In our new Health Affairs Scholar paper, led by Astrid Yu, we analyzed almost 7,000 cost-effectiveness analyses and found: CEAs in “most-favored nation” countries use considerably more stringent cost-effectiveness thresholds than the U.S. academic.oup.com/healthaffair... @tuftscevr.bsky.social

Conversations about drug pricing/value benefit from launch price transparency. New CEVR research finds that, from 2022-2024, pharma companies disclosed 1/3 of drug launch prices proactively and another 1/3 reactively, suggesting room for improvement. More at tinyurl.com/dsfjft4k

The best books I read in 2025. My annual list. cevr.tuftsmedicalcenter.org/news/best-bo...

What is the outlook for US payer coverage of specialty drugs in 2026? CEVR’s James Chambers will share insights from our SPEC database during a “can’t miss” webinar next week. When: December 18, 12-12:30 pm ET Register at tinyurl.com/56959f62

Our new @healthaffairs.bsky.social Forefront piece asks whether #Medicare's IPAY 2027 negotiated drug prices reflect value for money? tinyurl.com/2hcn3uun @tuftscevr.bsky.social evr.bsky.social @djvanness.bsky.social

The Centers for Medicare and Medicaid Services (#CMS) recently released the maximum fair prices (#MFP) for the 15 #IPAY 2027 drugs. How closely do they align with value-based prices? New CEVR research found wide variation, which sends muddled signals to drugmakers about value. tinyurl.com/3jsuybc7

Some drugmakers are rolling out “pharm-to-table” programs to sell drugs directly to patients at lower costs, but how much will these programs to improve access and price transparency? Read CEVR’s commentary on the promises and pitfalls of these programs. tinyurl.com/mrv8dczp

Is the "Pharm-to-Table" movement promising or performative? @brianreid.bsky.social and I have thoughts today in @healthaffairs.bsky.social Forefront. www.healthaffairs.org/content/fore...

Only 25% of cost-effectiveness analyses published from 2013-23 (n=7,800) omit societal costs (productivity, caregiving, travel, etc.), despite consensus guidelines recommending their inclusion. Read at tinyurl.com/3htu3zn9

Our new paper in Medical Decision Making finds that inclusion of societal costs in published cost-effectiveness analyses rose from 19%- 28% from 2013-2023, with variation across countries, diseases, & intervention types. @tuftscevr.bsky.social journals.sagepub.com/eprint/WBTRA... @smdm.bsky.social

From QALYs to Equal Value Life Years: Is Anyone Making the Shift? Some thoughts with Antony Martin. cevr.tuftsmedicalcenter.org/news/from-qa... @tuftscevr.bsky.social #HEOR #QALYs

Our new research letter in JAMA, led by James Chambers, highlights variation in how US commercial health plans impose coverage requirements for cell & #gene therapies. jamanetwork.com/journals/jam... @tuftscevr.bsky.social

Pleased to join this distinguished group of authors in paying tribute to the great John Iglehart, founding editor of Health Affairs, who passed away in June. tinyurl.com/47rnt9yf @tuftscevr.bsky.social @healthaffairs.bsky.social

New Tufts-CEVR research led by @pattysynnott.bsky.social highlights: - high out-of-pocket costs of older adults living with dementia - financial risks increase in advanced dementia states. alz-journals.onlinelibrary.wiley.com/doi/10.1002/... #Alzheimers #dementia

In this just published paper in Value in Health led by Feng Xie and colleagues, we reviewed the published cost-effectiveness evidence for the 15 drugs selected for IPAY 2027 Medicare negotiations. @djvanness.bsky.social @ankurfactorial.bsky.social www.valueinhealthjournal.com/article/S109...

@icer-review.bsky.social @tuftscevr.bsky.social @peterneumann11.bsky.social @pattysynnott.bsky.social

Welcome, Dave!

CEVR is thrilled to welcome David Strutton, PhD, as a Senior Fellow! Dr. Strutton brings 30+ years of global leadership in health policy, biopharma, and HTA. His expertise in real-world evidence and access strategy will be a tremendous asset. Read more at: tinyurl.com/3bz9te3p

Excited to announce that David Strutton, Ph.D., a distinguished leader in healthcare policy, biopharmaceuticals, #vaccines, and #healtheconomics is joining Tufts-CEVR as a Senior Fellow. Announcement here: cevr.tuftsmedicalcenter.org/news/david-s... @tuftscevr.bsky.social

Great application of our CEA Registry at the #Vanderbilt Center for Health Economic Modeling: 11 international fellows from #LMICs used the Registry to conduct CEAs of public health interventions. Read more at: tinyurl.com/88varaue @peterneumann11.bsky.social #ISPOR

New in JCER: CEVR’s Meng Li and @peterneumann11.bsky.social call for more value assessment of health services/procedures. These interventions are ~70% of health care spending but are often implemented without robust evidence and, unlike drugs, can cost more over time. Read: tinyurl.com/ycxrppby

Two weeks left to apply: Earn your #HEOR Certificate online from @tufts.edu with globally-recognized faculty like @peterneumann11.bsky.social, @dano-hta.bsky.social, James Chambers, and more from CEVR. Apply today! Deadline is Aug. 1. tinyurl.com/pr6drkhf #RWE #pharma

Larry Mose, MSc is today’s #CEARegistry Summer fellow. Larry earned his MSc from @york.ac.uk and hopes to work in the field of #HEOR. Our thanks to the @moorefound.bsky.social ‬for funding the CEA Registry Fellowship program!‬‬

1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:

Some personal reflections about John Iglehart (1939-1975), Founding Editor of Health Affairs. cevr.tuftsmedicalcenter.org/news/in-reme... @tuftscevr.bsky.social

New Tufts-CEVR paper in the J of Alzheimer's Disease, led by Paige Lin, provides updated health utility estimates for persons with AD and their caregivers across disease stages and settings. journals.sagepub.com/doi/10.1177/... @tuftscevr.bsky.social @pattysynnott.bsky.social #Alzheimers

Pleased to introduce the 2025 cohort of the Tufts-CEVR CEA Registry Summer Fellowship Program, supported by the Gordon and Betty Moore Foundation. cevr.tuftsmedicalcenter.org/news/2025-ce... @tuftscevr.bsky.social @pattysynnott.bsky.social

CEVR is thrilled to introduce the 2025 cohort of the Tufts-CEVR CEA Registry Summer Fellowship Program, which is supported by the @moorefound.bsky.social. Stay tuned over the next two months for featured posts about each fellow! More details at: cevr.tuftsmedicalcenter.org/news/2025-ce...

Congrats, Mel!

New in Value in Health: three former CEA Registry Summer Fellows (Xujun Gu, Hanwen Zhang, and Divya Patil) and U of Maryland's Julia Slejko used the CEA Registry to explore the utility of AI-assisted data extraction. Read at tinyurl.com/37mh5n6m

ISPOR and CEVR are partnering to offer free premium access to the CEA Registry for students + academic/government researchers in LMICs. Unlock data from 14,000+ cost-effectiveness studies, advanced tools, and more. More at: tinyurl.com/5y3vpsz3 #HEOR #GlobalHealth #ISPOR

We're excited to announce Tufts-CEVR's new partnership with ISPOR to provide free, premium access to the CEA Registry for ISPOR members who are students or researchers in LMICs. More detail here: cevr.tuftsmedicalcenter.org/news/cevr-is... @djvanness.bsky.social @tuftscevr.bsky.social

With @tuftscevr.bsky.social colleagues #ISPORAnnual in Montreal.

Thanks to all my wonderful Tufts-CEVR colleagues for putting on another great annual meeting! Proud to work with you! @dano-hta.bsky.social @brianreid.bsky.social @tuftscevr.bsky.social @mollytoba.bsky.social

Congrats!

This right question about prevention: not whether it saves money, but whether it is worth the cost. tinyurl.com/3ezrrvm4 @tuftscevr.bsky.social #health #prevention

Reports about the death of QALYs is greatly exaggerated. My new blog post: cevr.tuftsmedicalcenter.org/news/the-dea... @dano-hta.bsky.social @tuftscevr.bsky.social #HEOR #QALYs

Medicare coverage policy for new technologies may change substantially in the new Administration. Our analysis here: tinyurl.com/yuj67caf @healthaffairs.bsky.social @tuftscevr.bsky.social @kathrynp-phd.bsky.social

How will Trump admin reform Medicare’s #CED program? Return to the #MCIT paradigm, default enrollment in #Medicare Advantage, etc? In HA Forefront: Tunis, Hatfield, Patel, & @peterneumann11.bsky.social argue against removing CED + for efficient data collection. Read: tinyurl.com/yuj67caf

Our new piece in @healthaffairs.bsky.social on #Medicare coverage of new technologies in this new era. Key points: - CMS shouldn't eliminate coverage w/ evid development - instead, efforts should focus on more efficient post-market evidence generation. tinyurl.com/yu4rzkr2 @tuftscevr.bsky.social

New study by my @tuftscevr.bsky.social colleague, Yolanda Zhu and colleagues. The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities. tinyurl.com/5n8uxam3 #IRA #drugs

The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and multiple comorbidities. Read the new CEVR study in Value in Health for more details. authors.elsevier.com/a/1ke483vkP0...

This new podcast by Melanie Whittington interviewing @franksdavid.bsky.social provides a nice discussion about the use of models for investors and health economists. Well worth the listen. leerink.com/podcast/mana... @tuftscevr.bsky.social

Don't miss a chance to work with our renowned faculty! Applications for our 2025 CEA Registry Summer Fellowship close March 17th. Learn more / apply today: cevr.tuftsmedicalcenter.org/news/2025-ce... #internships #fellowship #healthecon @pattysynnott.bsky.social @peterneumann11.bsky.social

Thanks, @araymakers.bsky.social! @pattysynnott.bsky.social @dano-hta.bsky.social @tuftscevr.bsky.social @ankurfactorial.bsky.social

Good piece by @araymakers.bsky.social et al. using the Tufts CEA Registry: "Concerns over CEAs identifying subgroups in their analyses do not appear to be justified & does not warrant precluding the use of #QALYs for decision-making or price negotiation for drugs." @tuftscevr.bsky.social

We are now accepting applications for the our virtual Summer CEA Registry fellowship program. Learn more and apply here: cevr.tuftsmedicalcenter.org/news/2025-ce... #internships #fellowship #research #healthecon @tuftscevr.bsky.social @pattysynnott.bsky.social

Grad students: get a head start on summer by applying for our virtual CEA Registry fellowship. Learn more and apply today: cevr.tuftsmedicalcenter.org/news/2025-ce... #internships #fellowship #research #healthecon @pattysynnott.bsky.social

The best books I read in 2024. My annual list. tinyurl.com/yhs5h87v

Calling all health economists! The Tufts-CEVR Cost-Effectiveness Analysis Paper of the Year Contest is back! Submit your paper on cost-effectiveness analysis for a chance to win $500. Deadline: January 31, 2024. Don't miss out! Learn more & apply: tinyurl.com/yskfm9us #HEOR #CEA